Login to Your Account

Financings Roundup

Thursday, April 25, 2013
• Genticel SA, of Toulouse, France, raised €18.2 million (US$23.6 million) in a private equity round led by Wellington Partners, to move ProCervix, its bivalent therapeutic vaccine for combating human papillomavirus (HPV) infection into Phase II trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription